CEO Damien McDevitt, PhD, Featured in Biocom’s Article, “A Look at the Year Ahead for Life Sciences.”

Aspen Neuroscience’s CEO, Damien McDevitt, PhD, was featured in Biocom California’s article, “A Look at the Year Ahead for Life Sciences.”

Damien states, “The lack of treatment options for patients with neurodegenerative diseases remains a significant unmet medical need, especially options that slow down or cure the underlying disease pathogenesis. The development of cell therapy replacement approaches, in particular, those using autologous induced pluripotent stem cells (iPSCs) has opened up an exciting field, with potential for many different types of diseases. Aspen Neuroscience is a leader in autologous (cells from the same patients) iPSC discovery, leveraging advanced cell biology, manufacturing, and genomic/bioinformatics quality control technologies to characterize and develop the highest quality cell therapies. In the coming year, we are encouraged by several autologous iPSC-based cell therapies entering clinical development, including our lead program addressing Parkinson’s disease. We hope to replicate the remarkable success with CAR-T therapies for patients with Parkinson’s and other neurodegenerative diseases.”

The article can be found here: https://www.biocom.org/lifelines/interviews/a-look-at-the-year-ahead-for-life-sciences/


Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.